Authors
Christoper Hooper, Matthew Anderson, Sarah Bowen Jones, Corinne Faivre-Finn, Alastair Greystoke, Robert Rulach, Gerard Walls, Ashley Horne
Published in
Lung cancer (Amsterdam, Netherlands). Volume 221. Pages 109602. Aug 31, 2026. Epub Aug 31, 2026.
Abstract
Standard of care for inoperable and/or unresectable stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy followed by 12 months of adjuvant durvalumab. Many patients are ineligible due to poor fitness, comorbidity or concerns around their ability to tolerate concurrent therapy or immunotherapy. As a result, these patients experience inferior outcomes.
This article summarises four case studies initially presented at a UK-based academic webinar in August 2025. The focus of the webinar was the radiotherapy-based management of complex patients with stage III NSCLC. This included tumour factors (i.e. vascular invasion and bulky disease) and patient factors (i.e. interstitial lung disease, multiple comorbidities and frailty). Strategies to navigate these challenges and improve outcomes are highlighted.
Patients ineligible for standard-of-care treatment are under-represented in practice-defining trials. As a result, there is limited evidence to guide their management. Broader eligibility criteria and inclusive trials are needed to generate safety and efficacy data for this population. Enhanced phenotyping with biomarkers, adoption of advanced radiotherapy techniques, risk-adapted dose guidance and novel drug-radiotherapy combinations offer potential to expand access to curative-intent treatment and improve outcomes.
PMID:
42700509
Bibliographic data and abstract were imported from PubMed on 06 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0